Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

CORRECTION: Cytokinetics Q3 Adj. EPS $(1.54) Beats $(1.58) Estimate, Sales $1.936M Miss $3.556M Estimate

Author: Benzinga Newsdesk | November 05, 2025 06:44pm
Cytokinetics (NASDAQ:CYTK) reported quarterly losses of $(1.54) per share which beat the analyst consensus estimate of $(1.58) by 2.53 percent. This is a 13.24 percent decrease over losses of $(1.36) per share from the same period last year. The company reported quarterly sales of $1.936 million which missed the analyst consensus estimate of $3.556 million by 45.56 percent. This is a 318.14 percent increase over sales of $463.000 thousand the same period last year.

Posted In: CYTK


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist